Laddar...
Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion
Rapid initiation of eculizumab mitigates progression of carfilzomib-induced aHUS. Development of carfilzomib-induced aHUS may be associated with heterozygous CFHR3-CFHR1 deletion.
Sparad:
| I publikationen: | Blood Adv |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
American Society of Hematology
2018
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6290108/ https://ncbi.nlm.nih.gov/pubmed/30518536 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018027532 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|